Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 3/20 | 0.31 |
| ▸ | GABRD | O14764 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961818 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL13502386 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL6672007 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL20751905 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL12655751 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL1237085 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL1237086 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL31207017 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1TP53SLC7A5 | |
| SCHEMBL14702337 | 0.75 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1SLC7A5DPP4 | |
| SCHEMBL7396758 | 0.73 | ALDH1A1 (0.62) | ALDH1A1MAPTPTGS1TP53SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006120574-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | INNODIA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | ALDH1A1 600/4885MAPT 4044/4885PTGS1 775/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | ALDH1A1 615/4885MAPT 4338/4885PTGS1 854/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | ALDH1A1 300/4885MAPT 3954/4885PTGS1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.